| Name | Title | Contact Details |
|---|
One Community Bank is a locally owned community bank serving south-central Wisconsin. It was formed from the merger of Oregon Community Bank and McFarland State Bank and now serves 19 communities, including Oregon, Middleton, Sun Prairie, and Wausau. The bank is dedicated to providing personalized service and investing in local communities. The bank offers a wide range of personal and business banking services. Personal banking products include checking and savings accounts, certificates of deposit, money market accounts, mortgages, and consumer loans for various needs. For businesses, One Community Bank provides checking accounts with no minimum balance or monthly fees, interest-bearing options, and dedicated local bankers to assist with banking operations. One Community Bank emphasizes a client-centric approach, combining traditional banking with modern digital solutions like online and mobile banking. The bank is committed to community engagement through volunteerism and support for local nonprofits, reflecting its dedication to the well-being of the communities it serves.
Greater Iowa Credit Union (GICU) is a member-owned financial cooperative established in June 1932 by a group of Iowa State University employees. It has grown to serve over 36,000 members across a 33-county area in Central and Western Iowa, managing assets between $624 million and $667 million. GICU is federally insured and state-chartered, emphasizing its commitment to the financial well-being of its members and the communities it serves. GICU offers a range of financial services typical of credit unions, including banking services like checking and savings accounts, loans for personal, auto, and business needs, and possibly investment services. The credit union operates nine branch locations in cities such as Ames, Ankeny, and Des Moines, providing localized service. GICU is also dedicated to community engagement, having received recognition as the Best Credit Union in Crawford County and Story County multiple times.
DuBois Chemicals, Inc. is a prominent specialty chemical supplier with a history that dates back to 1920. Based in Hamilton, Ohio, the company is dedicated to providing innovative and economical solutions across various industries. DuBois focuses on delivering custom chemical solutions that enhance efficiency and reliability in industrial processes, emphasizing customer satisfaction and sustainability. The company offers a diverse product portfolio that includes cleaning and process solutions for general manufacturing, specialized chemicals for the pulp and paper industry, transportation cleaning solutions, and water treatment chemicals. With a significant facility in Cincinnati, Ohio, DuBois employs over 150 staff members, including scientists and customer service representatives, and has a strong sales team of over 400 representatives serving customers throughout North America. DuBois Chemicals demonstrates financial strength with revenues ranging from $100 million to $1 billion, allowing for continued investment in research and development.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.